You are here:

darunavir (Prezista)

Advice

following a full submission:

darunavir (Prezista®) 400mg is accepted for use within NHS Scotland.

Indication under review: darunavir 800mg once daily co-administered with low dose ritonavir (100mg once daily) for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count ≥100 cells/mm3.

Darunavir 800mg/ritonavir 100mg once daily was demonstrated to be non inferior to darunavir 600mg/ritonavir 100mg twice daily, when administered with an optimised background regimen that consisted of at least two nucleoside

Drug Details

Drug Name: darunavir (Prezista)
SMC Drug ID: 707/11
Manufacturer: Janssen-Cilag Ltd
Indication: For the treatment of HIV-1 infection in antiretroviral therapy (ART) experienced adults
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 August 2011

Back